Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 50 of 374

Guidance and quality standards awaiting development
Title	Type
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]	Technology appraisal guidance
Abdominal aortic aneurysm	Quality standard
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]	Technology appraisal guidance
Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]	Technology appraisal guidance
Acne	Quality standard
Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture [ID6276]	Technology appraisal guidance
Adrenal dysfunction	Quality standard
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care	Quality standard
Advocacy services for adults with health and social care needs	Quality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]	Technology appraisal guidance
AI technologies to aid the scoring and interpretation of diagnostic sleep studies	HealthTech guidance
AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735]	Technology appraisal guidance
Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754]	Technology appraisal guidance
Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746]	Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance
Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664]	Technology appraisal guidance
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]	Technology appraisal guidance
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance
Aprocitentan for treating resistant hypertension [ID6681]	Technology appraisal guidance
Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment	HealthTech guidance
Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care	HealthTech guidance
Artificial intelligence (AI)-derived software to help clinical decision making in stroke	HealthTech guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]	Technology appraisal guidance
Atrasentan for treating primary IgA nephropathy [ID6558]	Technology appraisal guidance
Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]	Technology appraisal guidance
Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]	Technology appraisal guidance
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]	Technology appraisal guidance
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]	Technology appraisal guidance
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]	Technology appraisal guidance
Bictegravir–lenacapavir for treating HIV-1 [ID6744]	Technology appraisal guidance
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis [ID4011]	Technology appraisal guidance
Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679]	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]	Technology appraisal guidance
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]	Technology appraisal guidance
Bupivacaine–meloxicam for treating postoperative pain [ID2728]	Technology appraisal guidance
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]	Technology appraisal guidance
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]	Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]	Technology appraisal guidance
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]	Technology appraisal guidance
Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]	Technology appraisal guidance

Results per page

10
25
50
All